Dyne Therapeutics reports BLA for z-rostudirsen accepted by FDA with Priority Review. The company also cleared an IND for DYNE-302 in FSHD, extending its pipeline via the FORCE platform.
Dyne Therapeutics reports BLA for z-rostudirsen accepted by FDA with Priority Review. The company also cleared an IND for DYNE-302 in FSHD, extending its pipeline via the FORCE platform.